SENS logo

Senseonics Holdings Inc. (SENS)

$10.90

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SENS

Market cap

$597107537

EPS

-2.27

P/E ratio

--

Price to sales

9.78

Dividend yield

--

Beta

1.044647

Price on SENS

Previous close

$10.58

Today's open

$10.34

Day's range

$10.30 - $11.53

52 week range

$4.79 - $13.98

Profile about SENS

CEO

Timothy T. Goodnow

Employees

130

Headquarters

Germantown, MD

Exchange

Nasdaq Global Select

Shares outstanding

54780508

Issue type

Common Stock

SENS industries and sectors

Healthcare

Medical Equipment & Supplies

News on SENS

BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas

Beta Bionics launches iLet Bionic Pancreas integration with Eversense 365, offering more CGM options and boosting growth prospects in the diabetes care market.

news source

Zacks Investment Research • 15 hours ago

news preview

Senseonics Holdings Sees $100 Million-Plus in 2027 Sales, Eyes New Eversense Launches

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS executives said the company's return of commercial operations in-house has improved efficiency and supported growth in its Eversense diabetes monitoring business, while outlining plans for new products and insulin pump partnerships.

news source

MarketBeat • Nov 11, 2026

news preview

Senseonics Revenue Surges 140% as New Pump Integration Nears Launch

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS reported quarterly revenue of $19.6 million, up 140% from a year earlier, as the continuous glucose monitoring company expands access to its implantable Eversense sensor and prepares for a new insulin pump integration.

news source

MarketBeat • Nov 12, 2026

news preview

Senseonics Holdings, Inc. (SENS) Q3 2026 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

What Senseonics Holdings, Inc. Common Stock (SENS) Said on Its Q3 Earnings Call

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS reported record third-quarter revenue and raised its 2026 sales outlook for the third time this year, as new patient starts for its Eversense 365 continuous glucose monitor drove growth in the United States and abroad.

news source

MarketBeat • Nov 9, 2026

news preview

Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results

Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98% Achieved gross margin of approximately 62% during Q3, and raising full-year gross margin guidance to more than 60% from 58% to 61% GERMANTOWN, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology, today announced third quarter 2026 financial results and provided a business update.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates

Senseonics Holdings (SENS) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.43 per share a year ago.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component

First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics' innovation roadmap, with potential launch in 2028

news source

GlobeNewsWire • Oct 26, 2026

news preview

Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences

GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November: Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY) Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10th.

news source

GlobeNewsWire • Oct 22, 2026

news preview

Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time

GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2026 financial results after market close on Monday, November 9, 2026.

news source

GlobeNewsWire • Oct 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Senseonics Holdings Inc.

Open an M1 investment account to buy and sell Senseonics Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SENS on M1